Pretrial Rulings Regarding Litigation Funding
It’s been said that non-pharma-related patent litigation tends to focus on a few big companies. Most are consumer-facing brands with their own retail outlets, though certainly not all. Those who make a career out of being a non-practicing entity (NPE) know who they are and how to target them. Above the Law explains that litigation funders are standing by to deploy funding to meritorious patent cases they deem worthy of support. Of course, companies used to being on the receiving end of patent lawsuits already have an array of countermeasures in place. The overwhelming majority of patent cases never actually make it to trial. They’re either settled early or stopped by a motion. Still, there’s much to be learned from studying the pretrial steps taken in this type of litigation. The case of Pinn v Apple involves a legal funder described as merely an “investor” in disclosure documents. After in limine motions regarding the size and main office locale of the plaintiff, the court ruled that the size and locations of counsel and their firms is not relevant to the facts of the case. Pinn sought to bar disclosure on litigation funding in the case, but the special master determined that the motion should be granted. Under most circumstances, the court said, matters related to funding should not take up time during a trial. If nothing else, the ruling suggests that disclosure of funding might be relevant in the early stages of a case—but as it nears trial, a discussion of funders and their motives is merely for show. Funders should be relieved to see that in patent cases, judges aren’t interested in focusing on funding agreements. Most courts seem to agree that patent litigation is complex enough without further complicating it with the intricacies of a funding arrangement. The ruling also suggests that defendants will need to be more strategic about how they manage cases with well-funded plaintiffs.